Orphanet: SAVVY CHILD: Phase III open label trial to determine the safety and tolerability of intracranial gene therapy in GM2 gangliosidosis using recombinant adeno associated viral vectors
x

Search for a networks

* (*) mandatory field

SAVVY CHILD: Phase I/II open-label trial to determine the safety and tolerability of intracranial gene therapy in GM2 gangliosidosis using recombinant adeno-associated viral vectors

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : CAMBRIDGE UNIVERSITY HOSPITALS 
  • Sponsor : Information not provided
  • Website
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - UK
  • ADDRESS: NOT PROVIDED - UK NYI UK
  • UNITED KINGDOM
  • More information
  • Phone  : -
  • Fax  : -
Last update: March 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.